Cranbrook Wealth Management’s Aerie Pharmaceuticals AERI Stock Holding History

Cranbrook Wealth Management’s Portfolio AERI Stock Details AERI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-500	Closed	-$24K	–	238
2017 Q3	$24K	Hold	500	–	–	0.01%	147
2017 Q2	$26K	Hold	500	–	–	0.01%	150
2017 Q1	$23K	Sell	500 -2,500	-83%	-$111K	0.01%	143
2016 Q4	$114K	Hold	3,000	–	–	0.06%	77
2016 Q3	$113K	Hold	3,000	–	–	0.06%	72
2016 Q2	$53K	Sell	3,000 -500	-14%	-$8.09K	0.03%	93
2016 Q1	$43K	Buy	3,500 +500	+17%	+$7.91K	0.02%	108
2015 Q4	$73K	Hold	3,000	–	–	0.04%	86
2015 Q3	$53K	Buy	3,000 +1,000	+50%	+$18.1K	0.03%	100
2015 Q2	$35K	Buy	2,000 +1,000	+100%	+$18.3K	0.02%	120
2015 Q1	$31K	Buy	+1,000	New	+$29K	0.02%	126

Other funds holding AERI

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cranbrook Wealth Management's AERI Position: Q4 2017 in Review

Cranbrook Wealth Management sold out of Aerie Pharmaceuticals (AERI) in Q4 2017, closing a stake of 500 shares — an estimated $24K sold.

Cranbrook Wealth Management first reported a position in AERI in Q1 2015 and held it in 11 quarters. The position peaked at $114K in Q4 2016. 179 funds tracked by Wall St. Rank hold AERI as of Q4 2017.

Cranbrook Wealth Management reported no remaining Aerie Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
Cranbrook Wealth Management sold 500 Aerie Pharmaceuticals shares in Q4 2017, an estimated $24K.
Cranbrook Wealth Management first reported a position in Aerie Pharmaceuticals in Q1 2015 and held it in 11 quarters.
Cranbrook Wealth Management's Aerie Pharmaceuticals position peaked at $114K in Q4 2016.
179 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2017.

Based on Cranbrook Wealth Management's 13F filing for Q4 2017, filed 7 Feb 2018.